| abstract |
Novel compounds of Formula I are provided: their stereoisomers and / or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl. , NHSO2R or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR 'wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n1 and n2 are independently selected from 0, 1 and 2. At least one of R3 and R4 and / or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, heteroatoms or functional groups such as O, N, SO2. Additionally, when R3 and R4 or R5 and R6 do not form a cyclic ring, then they can be independently selected from hydrogen, alkyl, branched alkyl and cycloalkyl. L1 is a linear aliphatic chain that optionally contains 4 to 16 carbon atoms. The chain can be optionally substituted one or more times by alkyl, branched alkyl, cycloalkyl or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano or COR7, wherein R7 is selected from hydroxy, alkyl, alkoxy or amine, NHR ', NHSO2R or NHCOR. Y1 is oxygen or hydrogen. Y2 is optional, where when Y2 is present, Y1 and Y2 are hydrogen. When Y2 is not present, Y1 is a carbonyl group. |